One of the most tragic experiences that anyone can have is watching a loved one succumb to the effects of Alzheimer’s Disease (AD). Axovant Sciences is on the forefront of clinical research for new pharmaceutical products that could help ease AD. Intepiridine, one of their developments, was among the new products that offered promise and hope for patients.
The Axovant Study and Intepiridine
Intepiridine was one of the latest efforts from specialists looking to provide hope and relief for those diagnosed with AD, or dementia with Lewy bodies present. In the late stages of the disease, as Lewy bodies build up, the symptoms of AD become worse. Lewy bodies affect the parts of the brain responsible for memory, thinking, and motor control.
The therapy goals for fighting against Alzheimer’s Disease is to prevent the further formation of late-stage Lewy bodies. At the outset of its clinical trials, Intepiridine was reported to be capable of reversing experimentally induced and age-related learning deficits in rats. The drug, however, does not target the formation of Lewy bodies but rather seemed to affect the memory.
Intepiridine was tolerated well by patient in a phase 1 clinical trial. The Phase 2 clinical trial looked promising, even though the benefits of the drug appeared to be marginal. When the time came for Phase 3 clinical trials, Axovant released marketing material promoting the benefits of the drug.
They promised to start investigating the drug for its effects on Lewey bodies in the future, but the negative results of the trial ended these hopes.
It appears that the company was overly optimistic on the capabilities of its new proposed drug therapy. The negative results were no better than those returned by the control group, and Axovant could not support its claims. Further research in this area is still very much needed, but apparently, it will not continue through Intepiridine.
Image Source: Pixabay